RNA-LP vaccine

The **RNA-LP vaccine** is an investigational cancer immunotherapy composed of patient-derived messenger RNA (mRNA) encapsulated within **lipid nanoparticles (LNPs)**, forming an RNA-lipid particle (RNA-LP). The vaccine is highly personalized, with RNA amplified from an individual’s tumor and used to encode tumor-specific antigens. This mRNA is then wrapped in biocompatible lipid particles to protect it from degradation, enable efficient delivery, and enhance uptake by immune cells. Upon administration, the vaccine leads to robust activation of adaptive immunity, reprograms the tumor microenvironment (TME) from immunologically "cold" to "hot," and drives a vigorous and rapid anti-tumor immune response. This approach aims to overcome limitations of prior cancer vaccines, with the multi-lamellar ("onion-like") LNP structures enabling enhanced delivery and immunogenicity. Mechanistically, the RNA-LP vaccine delivers mRNA encoding tumor antigens to antigen-presenting cells, resulting in antigen expression, presentation via major histocompatibility complex (MHC) class I pathways, and subsequent activation of cytotoxic T lymphocytes targeting tumor cells. The LNP serves both as a delivery vector and an adjuvant, further augmenting immune activation. The RNA-LP vaccine is currently in early clinical trials (Phase 1/2) in oncology, notably in glioblastoma and other solid tumors[2][8].

Other names

ribonucleic acid-lipid nanoparticle vaccine